Abstract
This open label study determined the outcome of non-AIDS progressive multifocal leukoencephalopathy patients treated with a standard dose of intravenous cytosine arabinoside. Nineteen patients with PML proven by brain biopsy or spinal fluid polymerase chain reaction were treated with intravenous cytosine arabinoside 2 mg/kg per day for 5 days and followed for neurologic outcome by neurologic examination and MRI scanning. Seven of 19 PML patients treated with cytosine arabinoside intravenously improved neurologically. The range of follow-up for these patients was 2.0 to 4.5 years. All were left with neurologic deficits but were functionally improved, and 6 of 7 were able to independently carry out the activities of daily living. Twelve PML patients showed no evidence of response and died rapidly of their disease after treatment (range, 8 days to 6 months). All who survived their neurologic disease recovered from treatment-induced pancytopenia. Cytosine arabinoside given intravenously to non-AIDS PML patients in this small study was associated with a 36% chance of developing stabilization at 1 year. Treatment was associated with significant bone marrow toxicity. The improvement in MRI scan changes in those patients who responded took 6 weeks or longer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aksamit AJ Jr (1993). Nonradioactive in situ hybridization in progressive multifocal leukoencephalopathy. Mayo Clin Proc 68(9): 899–910.
Bauer WR, Turel AP Jr, Johnson KP (1973). Progressive multifocal leukoencephalopathy and cytarabine. Remission with treatment. JAMA 226(2): 174–176.
Berger JR, Mucke L (1988). Prolonged survival and partial recovery in AIDS-associated progressive multifocal leukoencephalopathy. Neurology 38(7): 1060–1065.
Brooks BR, Walker DL (1984). Progressive multifocal leukoencephalopathy. Neurol Clin 2(2): 299–313.
Clifford DB, Yiannoutsos C, Glicksman M, Simpson DM, Singer EJ, Piliero PJ, Marra CM, Francis GS, McArthur JC, Tyler KL, Tselis AC, Hyslop NE (1993). HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy. Neurology 52(3): 623–625.
Hall CD, Dafni U, Simpson D, Clifford D, Wetherill PE, Cohen B, McArthur J, Hollander H, Yainnoutsos C, Major E, Millar L, Timpone J (1998). Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team. N Engl J Med 338(19): 1345–1351.
Kepes JJ, Chou SM, Price LW Jr (1975). Progressive multifocal leukoencephalopathy with 10-year survival in a patient with nontropical sprue. Report of a case with unusual light and electronmicroscopic features. Neurology 25(11): 1006–1012.
Lidman C, Lindqvist L, Mathiesen T, Grane P (1991). Progressive multifocal leukoencephalopathy in AIDS. AIDS 5(8): 1039–1041.
Marriott PJ, O’Brien MD, Mackenzie IC, Janota I (1975). Progressive multifocal leucoencephalopathy: remission with cytarabine. J Neurol Neurosurg Psychiatry 38(3): 205–209.
Nicoli F, Chave B, Peragut JC, Gastaut JL (1992). Efficacy of cytarabine in progressive multifocal leucoencephalopathy in AIDS. Lancet 339(8788): 306.
O’Riordan T, Daly PA, Hutchinson M, Shattock AG, Gardner SD (1990). Progressive multifocal leukoencephalopathy-remission with cytarabine. J Infect 20(1): 51–54.
Peters AC, Versteeg J, Bots GT, Boogerd W, Vielvoye GJ (1980). Progressive multifocal leukoencephalopathy: immunofluorescent demonstration of simian virus 40 antigen in CSF cells and response to cytarabine therapy. Arch Neurol 37(8): 497–501.
Portegies P, Algra PR, Hollak CE, Prins JM, Reiss P, Valk J, Lange JM (1991). Response to cytarabine in progressive multifocal leucoencephalopathy in AIDS. Lancet 337(8742): 680–681.
Price RW, Nielsen S, Horten B, Rubino M, Padgett B, Walker D (1983). Progressive multifocal leukoencephalopathy: a burnt-out case. Ann Neurol 13(5): 485–490.
Rockwell D, Ruben FL, Winkelstein A, Mendelow H (1976). Absence of immune deficiencies in a case of progressive multifocal leukoencephalopathy. Am J Med 61(3): 433–436.
Saxton C, Gailiunas P Jr, Helderman JH, Farkas RA, McCoy R, Diehl J, Sagalowsky A, Murphy FK, Ross ED, Silva FR (1984). Progressive multifocal leukoencephalopathy in a renal transplant recipient. Increased diagnostic sensitivity of computed tomographic scanning by double-dose contrast with delayed films. Am J Med 77(2): 333–337.
Schlitt M, Morawetz RB, Bonnin J, Chandra-Sekar B, Curtiss JJ, Diethelm AG Jr, Whelchel JD, Whitley RJ (1986). Progressive multifocal leukoencephalopathy: three patients diagnosed by brain biopsy, with prolonged survival in two. Neurosurgery 18(4): 407–414.
Steiger MJ, Tarnesby G, Gabe S, McLaughlin J, Schapira AH (1993). Successful outcome of progressive multifocal leukoencephalopathy with cytarabine and interferon. Ann Neurol 33(4): 407–411.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Aksamit, A.J. Treatment of non-AIDS progressive multifocal leukoencephalopathy with cytosine arabinoside. Journal of NeuroVirology 7, 386–390 (2001). https://doi.org/10.1080/13550280152537292
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1080/13550280152537292